In healthcare, they say the only constant is change. Medical practices and treatments are always evolving, and today's guest is on the cutting edge of an exciting development. Today we're sitting down with Dr. Eddie Sullivan, co-founder, President and CEO at SAB Biotherapeutics. Eddie served in biopharma leadership positions for more than 25 years, and prior to joining SAB, he was CEO of Hema Tech, where he led initiatives to develop infectious disease, cancer, and autoimmune immunotherapies. A recognized thought leader in antibodies in transgenic animals, Eddie serves on the board of directors for the Biotechnology Innovation Organization, he's earned two PhDs in health science administration and reproductive physiology, and he holds an MS in reproductive physiology and molecular biology, and a BS in Animal health sciences.On the show, we talk to Eddie about SAB's polyclonal antibody research, perceptions about this research in the biotech world, and the future of fighting diseases. Highlights:Eddie's path to the Biotherapeutics field (3:04)Founding SAB and the immunotherapy industry (3:41)How SAB uses cows for research (4:59)SAB's take on the COVID vaccine (8:43)Perceptions of monoclonals vs. polyclonals (13:27)Slow growth in polyclonal research (16:57)SAB's work on Type 1 Diabetes and other disease treatment (20:13)What Eddie is excited about in the future for the field (26:19)The biggest challenge in biotech (27:10)Links:ICR TwitterICR LinkedInICR WebsiteDr. Eddie Sullivan on LinkedInSAB Biotherapeutics on LinkedinSAB Biotherapeutics WebsiteFeedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, [email protected].

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related